Synthetic lethality in cancer treatment – Ryvu Therapeutics seminar

Read More

SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021

Read More

Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland

Read More

Ryvu Therapeutics announces participation in the UBS 2021 Global Healthcare Virtual Conference and the Erste Group Innovation Conference 2021

Read More

Ryvu Therapeutics presents at STING- & TLR-Targeting Therapies Summit

Read More

Ryvu Therapeutics to Present Clinical and Translational Data from RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. New clinical abstract on SEL24(MEN1703) also available.

Read More

Ryvu Therapeutics Reports First Quarter 2021 Financial Results

Read More

Ryvu Therapeutics appoints Vatnak Vat-Ho as Chief Business Officer

Read More

Ryvu Announces Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Read More

Ryvu Therapeutics at BIO-Europe Spring

Read More